Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Fate Therapeutics ($FATE) announced the start of Phase 2 segment of its Phase 1/2 clinical trial, PROTECT, assessing ProTmune for the prevention of acute graft-versus-host disease (GvHD) in patients with blood cancers undergoing matched unrelated donor hematopoietic cell transplantation. The Phase 2 study will evaluate the safety and efficacy of ProTmune in 60 patients who will be randomized 1:1 to receive either ProTmune or a conventional matched unrelated donor mobilized peripheral blood cell graft.
The company gained over 2 percent in its previous trading session, taking its Year to Date gain to 69 percent.

Second Sight Medical Products Inc. ($EYES) stock reacted positively to the news as the company reported a positive article about its new implant, the Orion, in the MIT’s Technology Review. The implant is a modified version of the Argus II Retinal Prosthesis System. The FDA has signed off a small five-subject study to further test the device before starting larger-scale trials. Orion involves the placement of an array of electrodes on the part of the brain that processes visual information.
Second Sight Medical Products develops, manufactures and markets prosthetic devices that restore vision to blind individuals.


OncoCyte Corporation ($OCX) reported positive final results from the Analytical Validation Study of its liquid biopsy lung cancer diagnostic test, DetermaVU. The accuracy results of the study demonstrate sensitivity of 94.4%, specificity of 67.5% and Area Under the Curve of 0.93, showed that 93% of the samples tested were correctly diagnosed. The Company believes DetermaVu will be the only commercially available liquid biopsy lung cancer product.
BioTime ($BTX) received a grant of up to $1.56 million from the Small Business Innovation Research program of the National Institutes of Health. The grant will fund further develop restoration program for advanced retinal diseases and injuries.

Perrigo ($PRGO) received the tentative approval from the FDA for its generic version of Valeant Pharmaceuticals' acne treatment ACANYA (clindamycin phosphate and benzoyl peroxide) Gel. Tentative approval means that the company's marketing application meets the standards for approval, however, patent issues need to be resolved. The company responded that it has settled litigation with Valeant and Dow Pharmaceutical Services.

Medtronic plc ($MDT) reported the FDA approval for its next-generation spinal cord stimulator (SCS) for the management of certain types of chronic intractable pain, Intellis. The company also announced the commercial launch of the product in the US.


Pain Therapeutics ($PTIE) reported receiving the award of a $2.2 million grant from the National Institute on Drug Abuse (NIDA) to support development of pain candidate FENROCK, an abuse-deterrent transdermal patch formulation of fentanyl.

Quidel ($QDEL) reported amending its previously announced agreements with Alere. The agreement encompassed purchase of Alere’s B-type Naturietic Peptide (BNP) business and Triage MeterPro cardiovascular and toxicology assets. Quidel will assume direct commercial responsibility for global BNP sales on Beckman Coulter analyzers. It will pay up to $680 million for the assets, $400 million for Triage, $40 million in contingent consideration for the EEA BNP business and $240 million in deferred consideration for the rest-of-world BNP business.

Brokerage Action Company Rating
Royal Bank Of Canada Initiates AmerisourceBergen Corporation (Holding Co) (ABC)
Sector Perform
Royal Bank Of Canada Initiates athenahealth (ATHN)
Sector Perform
Cowen and Company Reiterates Bristol-Myers Squibb Company (BMY)
Royal Bank Of Canada Initiates Cardinal Health (CAH)
Sector Perform
Royal Bank Of Canada Initiates Cerner Corporation (CERN)
Top Pick
Royal Bank Of Canada Initiates Charles River Laboratories International (CRL)
Sector Perform
Citigroup Downgrades Dimension Therapeutics (DMTX)
Neutral -> Sell

Gainers (% price change) Last Trade Change Mkt Cap
Quidel Corporation QDEL 40.91 +5.10 (14.24%) 1.37B
Progenics Pharmaceuticals PGNX 7.10 +0.73 (11.46%) 498.92M
Clovis Oncology Inc CLVS 76.74 +7.28 (10.48%) 3.75B
GenMark Diagnostics, Inc GNMK 9.65 +0.73 (8.18%) 527.54M
Athersys, Inc. ATHX 2.38 +0.16 (7.21%) 271.11M
Losers (% price change)
Kindred Healthcare, Inc. KND 6.65 -0.60 (-8.28%) 578.68M
Cardiovascular Systems CSII 28.25 -2.20 (-7.22%) 932.02M
Teva Pharmaceutical TEVA 16.99 -1.11 (-6.13%) 17.88B
Tenet Healthcare Corp THC 15.72 -1.01 (-6.04%) 1.58B
BioDelivery Sciences Intl BDSI 2.70 -0.15 (-5.26%) 149.79M
Most Actives (dollar volume)
Johnson & Johnson JNJ 135.38 +0.93 (0.69%) 363.36B
Merck & Co., Inc. MRK 65.99 -0.17 (-0.26%) 179.98B
Gilead Sciences, Inc. GILD 82.97 +0.61 (0.74%) 108.35B
Pfizer Inc. PFE 35.55 +0.19 (0.54%) 211.70B
Teva Pharmaceutical TEVA 16.99 -1.11 (-6.13%) 17.88B